Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1030 | 1050 | 1057 | 1176 | 1381 | 2080 |
Fund Return | 3.04% | 4.97% | 5.68% | 5.55% | 6.66% | 7.6% |
Place in category | 132 | 254 | 152 | 38 | 113 | 12 |
% in Category | 19 | 38 | 26 | 9 | 26 | 5 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 9B | 18.17 | 9.14 | 13.09 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.13B | 16.91 | 7.54 | 10.23 | ||
UBS CH Vitainvest 50 World U | 4.32B | 2.45 | -0.62 | 2.66 | ||
UBS CH Institutional Fund 2 EquUSAA | 2.17B | 18.12 | 8.92 | 12.85 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.35B | 11.77 | 0.06 | 7.48 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.34B | 6.76 | 5.03 | 6.69 | ||
Raiffeisen Futura Swiss Stock A | 2.07B | 2.12 | 2.41 | 6.12 | ||
UBS CH Equity Fund Swiss Income CHF | 2.03B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.03B | 2.59 | 4.20 | 6.41 | ||
UBAM Swiss Equity AD CHF Inc | 1.72B | 7.99 | -0.55 | 5.90 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Roche Holding Participation | CH0012032048 | 9.63 | 217.30 | +1.49% | |
Novartis | CH0012005267 | 9.27 | 87.97 | -1.01% | |
Nestle | CH0038863350 | 9.16 | 91.72 | -0.11% | |
UBS Group | CH0244767585 | 8.86 | 24.59 | +1.24% | |
Zurich Insurance Group | CH0011075394 | 7.55 | 439.00 | -0.39% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Strong Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review